HVB MINI FUTURE BULL - ASTRAZENECA | Real-time BOERSE MUENCHEN 10:47:05 17/05/2024 BST | ||
| 6.46 EUR | +0.31% |
|
| Current month | +1.26% | ||
| 1 month | +26.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 6.46 | +0.31% |
| 16/05/24 | 6.44 | -0.77% |
| 15/05/24 | 6.49 | -1.37% |
| 14/05/24 | 6.58 | -0.45% |
| 13/05/24 | 6.61 | -1.20% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 10:47 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR5TXY |
| ISIN | DE000HR5TXY2 |
| Date issued | 25/02/2021 |
| Strike | 6,603 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.36 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.94 € |
|---|---|
| Lowest since issue | 0.98 € |
| Spread | 0.01 € |
| Spread % | 0.16% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
154.2
USD
Average target price
167.6
USD
Spread / Average Target
+8.70%
- Stock Market
- Certificates
- Certificat
